1 publication

• Published Subscription 25 Jan 2024

  Risperidone: A Silver Lining In Mental Disorders

  By Nikita Gurav, Dhanshree Patil, Shweta Patil, Sayali Nejkar

  Abstract: Risperidone (RYKINDO®) is second generation benzisothiazole which elevates linkage to serotonin type 2 (5HT2A) and dopamine type 2(D2) receptor developed by Luye Pharma Group used in short term palliative treatment of aggression or psychopathic disorders. Both 5HT2 antagonism with D2 receptor, it selectively bind to 5HT2A antagonist and shows neuroleptic effect by Risperidone. It is also available in the form of oral solution and disintegrating tablet etc. It is long …

  Published in Research & Reviews: A Journal of Drug Formulation, Development and Production · Vol. 10, Issue 3, 2023 · pp. 11–21 Read article →